Søren Lemonius
Chief Executive Officer bei Sunstone LSV & Co. Special Limited Partner III Holding ApS
Ursprung des Netzwerks ersten Grades von Søren Lemonius
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Sunstone Capital A/S
 Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors.
20
| Private Company | Investment Managers | 20 |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.
15
| Subsidiary | Miscellaneous Commercial Services | 15 |
| Extinct | Pharmaceuticals: Major | 11 | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.
11
| Subsidiary | Pharmaceuticals: Major | 11 |
Synendos Therapeutics AG
 Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland.
6
| Holding Company | Medical Specialties | 6 |
Sunstone LSV General Partner I ApS
2
| Private Company | 2 | |
Sunstone LSV General Partner BI ApS
2
| Private Company | 2 | |
Sunstone LSV Management A/S
2
| Subsidiary | 2 | |
Nuevolution A/S
 Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Sunstone LSV GP BI Holding ApS
1
| Private Company | 1 | |
Sunstone Lsv Partners Holding ApS
1
| Private Company | 1 | |
Sunstone Lsv Partners & Co. Holding ApS
1
| Private Company | 1 | |
Foss Analytical A/S
 Foss Analytical A/S Electronic Equipment/InstrumentsElectronic Technology Foss Analytical A/S engages in manufacturing and trading. The firm manufactures equipment for measuring, testing, and navigation. It wholesales other machinery and equipment. The company was founded on December 14, 1983 and is headquartered in Hillerød, Denmark.
1
| Subsidiary | Electronic Equipment/Instruments | 1 |
Sunstone LSV Gp I Holding ApS
1
| Private Company | 1 | |
Sunstone Life Science Ventures A/S
 Sunstone Life Science Ventures A/S Financial ConglomeratesFinance Part of Sunstone Capital A/S, Sunstone Life Science Ventures A/S is a Danish company that provides investment services. The private company is based in Copenhagen, Denmark.
1
| Subsidiary | Financial Conglomerates | 1 |
Sunstone LSV Special LP II Holding Aps
1
| Private Company | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Søren Lemonius
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Chief Investment Officer | |
| University of Oxford | College/University | Undergraduate Degree Graduate Degree | |
| University of Cambridge | College/University | Director/Board Member Masters Business Admin | |
Danmarks Eksport- og Investeringsfond
 Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Investment Managers | Head-Equity Investments Head-Equity Investments Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Chief Investment Officer | |
| CELLAVISION AB | Medical Specialties | Director/Board Member Director/Board Member | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Undergraduate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Technical University of Denmark | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree Graduate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree Undergraduate Degree Graduate Degree Doctorate Degree Undergraduate Degree | |
| University of Basel | College/University | Doctorate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree | |
| SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor Private Equity Investor | |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Life Science Ventures
 Life Science Ventures Investment ManagersFinance Life Science Ventures provides financial advice. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
FlatFrog Laboratories AB
 FlatFrog Laboratories AB Packaged SoftwareTechnology Services FlatFrog Laboratories AB designs and manufactures optics-based multi-touch kits and subsystems. Its product detects pressure, which creates ways for users to interact with content. The firm incorporates FlatFrog technology into products such as multi-touch tabletops, digital signage and whiteboards, point-of-sale, gaming and medical displays, and consumer electronics, such as note-/net-book computers, desktop monitors, and multi-touch input pads. The company was founded by Ola Wassvik and Lars Christer Fredrik Fåhraeus in 2007 and is headquartered in Lund, Sweden. | Packaged Software | Director/Board Member Director/Board Member | |
| Heartcore General Partner I ApS | Director/Board Member Director/Board Member | ||
| EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member Chairman Founder Corporate Officer/Principal Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
Zymenex Holding A/S
 Zymenex Holding A/S BiotechnologyHealth Technology Zymenex Holding A/S engages in the research and development of therapeutics for life threatening diseases. The company is headquartered in Hillerod, Denmark. | Biotechnology | Director/Board Member Chairman | |
| CANTARGIA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| BOOZT AB | Catalog/Specialty Distribution | Director/Board Member Director/Board Member Director/Board Member | |
| Heartcore Capital A/S | Investment Managers | Founder Founder Private Equity Investor Director/Board Member Private Equity Investor Director of Finance/CFO | |
| Sunstone TV Partners & Co. Holding ApS | Director/Board Member Director/Board Member | ||
| Sunstone TV Partners Holding ApS | Director/Board Member Director/Board Member | ||
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| DEXTECH MEDICAL AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Sunstone LSV Partners Holding III ApS | Corporate Officer/Principal Chief Executive Officer | ||
| Sunstone LSV Invest III Holding ApS | Corporate Officer/Principal Chief Executive Officer | ||
| Sunstone LSV Invest III ApS | Corporate Officer/Principal Chief Executive Officer | ||
| Sunstone LSV Special Limited Partner III Aps | Corporate Officer/Principal Chief Executive Officer | ||
Albumedix A/S
 Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
| Sunstone Lsv Special Ltd. Partner Iii Holding Aps | Corporate Officer/Principal Chief Executive Officer | ||
| GALECTO, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Chairman Director/Board Member Chief Operating Officer Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member |
Statistik
International
| Dänemark | 28 |
| Schweiz | 8 |
| Schweden | 7 |
| Vereinigtes Königreich | 4 |
| Deutschland | 2 |
Sektoral
| Health Technology | 23 |
| Consumer Services | 7 |
| Finance | 6 |
| Commercial Services | 4 |
| Technology Services | 3 |
Operativ
| Director/Board Member | 513 |
| Corporate Officer/Principal | 153 |
| Chairman | 113 |
| Independent Dir/Board Member | 66 |
| Chief Executive Officer | 58 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Søren Lemonius
- Unternehmensverbindungen
